Predictive Factors of Acute Symptomatic Seizures in Patients With Ischemic Stroke Due to Large Vessel Occlusion

Lisa Marie Tako 1,2, Adam Strzelczyk 1,2, Felix Rosenow 1,2, Waltraud Pfeilschifter 3, Helmuth Steinmetz 1, Rejane Golbach 4, Jan Hendrik Schäfer 1, Johann Philipp Zöllner 1,2 and Konstantin Kohlhase 1

1 Department of Neurology, Epilepsy Center Frankfurt Rhine-Main, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany; 2 LOEVE Center for Personalized and Translational Epilepsy Research, Goethe University Frankfurt, Frankfurt, Germany; 3 Department of Neurology and Neurophysiology, Lüneburg Hospital, Lüneburg, Germany; 4 Institute of Biostatistics and Mathematical Modelling, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany

Introduction: Acute symptomatic seizures (ASz) after ischemic stroke are associated with increased mortality; therefore, identifying predictors of ASz is important. The purpose of this study was to analyze predictors of ASz in a population of patients with ischemic stroke due to large arterial vessel occlusion (LVO).

Materials and Methods: This retrospective study examined patients with acute ischemic stroke caused by LVO between 2016 and 2020. Identification of predictive factors was performed using univariate and subsequent multiple logistic regression analysis. In addition, subgroup analysis regarding seizure semiology and time of seizure occurrence (≤ 24 h and > 24 h after stroke) was performed.

Results: The frequency of ASz among 979 patients was 3.9 % (n = 38). Univariate logistic regression analysis revealed an increased risk of ASz in patients with higher National Institutes of Health Stroke Scale (NIHSS) score at admission or 24 h after admission, hypernatremia at admission ≥ 145 mmol/L, and pneumonia. Further multiple logistic regression analysis revealed that NIHSS 24 h after admission was the strongest predictor of ASz, particularly relating to ASz occurring later than 24 h after stroke. Patients who experienced a seizure within the first 24 h after stroke were more likely to have a generalized tonic-clonic (GTCS) and focal motor seizure; beyond 24 h, seizures with impaired awareness and non-convulsive status epilepticus were more frequent.

Conclusion: NIHSS score 24 h after admission is a strong predictive factor for the occurrence of ASz in patients with ischemic stroke caused by LVO. The semiology of ASz varied over time, with GTCS occurring more frequently in the first 24 h after stroke.

Keywords: epilepsy, seizure, intravenous thrombolysis, mechanical recanalization, stroke unit
INTRODUCTION

Cerebrovascular disease is the most common cause of epilepsy in the elderly, accounting for up to 39–49% of all newly diagnosed epilepsies in patients aged > 60 years (1, 2). Due to demographic changes, the incidence of stroke-related epilepsy is expected to rise and pose an increasing challenge for the healthcare system (3). Depending on the time course, seizures after stroke are defined according to the International League Against Epilepsy (ILAE) either as an acute symptomatic seizure (ASz) if they occur within 7 days, or as an unprovoked late seizure if they occur later than 7 days (4). Acute symptomatic seizures are thought to result from local cellular biochemical dysfunction of electrically excitable tissues, whereas late seizures are caused by post-ischemic remodeling of the damaged brain tissue and neuronal network, leading to an acquired predisposition to seizures and the diagnosis of post-stroke epilepsy (5–8). A large systemic review and meta-analysis examined the frequency of seizures after ischemic stroke; the frequency of ASz was found to be 3.3% and the late post-stroke seizure frequency was 1.8% (9). Because ASz are associated with an increased risk of mortality, knowledge of predictive factors is essential (10, 11). Various risk factors with different levels of evidence are described in the literature. The severity of stroke, estimated by the National Institutes of Health Stroke Scale (NIHSS), and cortical involvement were identified as independent risk factors for the occurrence of ASz (11–16). Data are inconclusive regarding other possible risk factors, such as cardioembolic infarct etiology, anterior circulation cerebral infarction, hemorrhagic transformation, previous transient ischemic attack (TIA), acute non-neurological infection, and history of diabetes mellitus (10, 11, 13, 17). Based on these results, different prediction models have been developed to assess the individual risk for post-stroke seizures (18, 19). Furthermore, therapy with statins in the acute phase of stroke was reported to reduce the rate of seizures (20). Systemic thrombolysis and mechanical thrombectomy as established reperfusion procedures have also been the subject of research, with recent studies showing no association with ASz frequency (21, 22).

The variability among identified predictive factors may be explained by the heterogeneous designs of the available studies, with varying levels of evidence (registry studies, retrospective and prospective designs, mono- or multi-centric studies, systematic reviews), inclusion criteria (hemorrhagic and ischemic stroke), and definitions of ASz occurring later than 7 days (17, 23, 24). Furthermore, the studies were conducted over an extended period, including several studies in which neurological treatment in stroke units differed and new therapeutic milestones, such as mechanical recanalization, had not yet been established.

The purpose of this study is to analyze predictive factors for ASz in a well-defined patient population who experienced an ischemic stroke due to large vessel occlusion (LVO) and who were treated after mechanical recanalization had become the standard therapy for LVO in 2016.

MATERIALS AND METHODS

This study analyzed data from patients with acute ischemic stroke who were treated at the University Hospital Frankfurt between 2016 and 2020. The Local Ethics Committee of Goethe University Frankfurt approved the study (IRB: 19-285). Due to the retrospective design of this study, the requirement for written informed consent of the patients was waived. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were closely followed (25).

We included patients with a final International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) diagnosis of “acute ischemic stroke caused by an occlusion of a large cerebral vessel.” The occlusion of a large cerebral vessel was confirmed either by imaging with CT or MR angiography, or by infarct demarcation that could only be explained by a proximal vessel occlusion. LVO was defined according to the literature as an occlusion of the internal carotid artery, middle cerebral artery (including M1 and M2 segments), anterior cerebral artery (including A1 and A2 segments), posterior cerebral artery (including P1 and P2 segments), vertebral artery, or basilar artery. LVOs were further divided into either anterior (internal carotid artery, middle cerebral artery, and anterior cerebral artery) or posterior (posterior cerebral artery, vertebral artery, and basilar artery) circulation.

The collected data contained the following variables: age; sex; NIHSS score at admission, 24 h after admission, and at discharge; modified Rankin Scale (mRS) score prior to stroke and at discharge; type of LVO; stroke etiology according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria (26); history of arterial hypertension, diabetes mellitus, atrial fibrillation, chronic alcohol consumption, previous stroke, and brain tumor; known neurodegenerative disease; previous treatment with oral anticoagulants, antiplatelet agents, or statins; serum level of sodium (mmol/L), glucose (mg/dl), and total cholesterol (mg/dl) at admission; and hemorrhagic transformation. In addition, preexisting treatment with anti-seizure medication (ATC code N03A irrespective of indication, e.g., mood stabilizer or management of neuropathic pain) was ascertained. Furthermore, treatment with mechanical thrombectomy or systemic thrombolysis was assessed. In patients who underwent mechanical thrombectomy, the outcome of mechanical recanalization was reported according to the TICI (thrombolysis in cerebral infarction) grading system, with a score of at least 2b considered successful reperfusion (27). Mechanical thrombectomy is routinely performed under general anesthesia with subsequent weaning on the intensive care unit. The occurrence of pneumonia during hospital stay was assessed, which was defined by radiological evidence of pneumonia-compatible findings (e.g., infiltrates, consolidation) with associated clinical (e.g., purulent sputum, hypoxia, dyspnea, tachypnea, pathologic auscultation of the lungs, fever > 38.3°C) and laboratory signs (e.g., leukopenia < 4,000 leukocytes/mm³, leukocytosis > 12,000/mm³).
An ASz was defined as either clinically observed ictal stigmas or subclinical seizure patterns or non-convulsive status epilepticus (NCSE) recorded on electroencephalography (EEG) within the first 7 days after stroke (seizure latency) (4). EEG was performed according to the indication of the attending physician; standard continuous EEG diagnostics was not performed. There was no prophylactic antiseizure medication administered after ischemic stroke. Further subgroup analysis was performed for seizures occurring ≤ 24 h and later than 24 h until 7 days of stroke onset. Based on the reported semiology and EEG patterns, seizures were subdivided into: (I) seizures with impaired awareness or NCSE, (II) focal motor seizures, and (III) generalized tonic-clonic seizures (GTCS) (28).

For the regression analysis, we further divided the numerical and ordinally scaled variables into categories. NIHSS score was divided into three groups: 0-5 points, corresponding to none or mild neurological deficit; 6-15 points, corresponding to moderate neurological deficit; and more than 15 points, corresponding to severe neurological deficit. We also divided the mRS score into two groups: 0-5 points for patients with no significant or only mild neurological deficit; 6-15 points, corresponding to moderate-to-severe disability. Furthermore, sodium level at admission was classified as hyponatremia (≤ 135 mmol/L), normal (136–144 mmol/L), or hypernatremia (≥ 145 mmol/L). The glucose level was classified as hypo- (≤ 50 mg/dl) or hyperglycemia (≥ 200 mg/dl).

Statistical analyses were performed using SPSS (version 27.0.1.0, IBM Corp., Armonk, NY, USA). For statistical evaluation, univariate binary logistic regression analysis was initially performed for independent variables, with ASz as the dependent variable. Based on this analysis, significant (p-value < 0.1) independent variables were selected for further multiple binary logistic regression analysis. Due to a total of 38 ASz, the number of covariates to be included was limited to 4 variates (the number of positive cases in the independent variable divided by 10). Intergroup differences in seizure semiology regarding time of occurrence were calculated using the chi-squared test. P-values were corrected for multiple testing by using the Benjamini–Hochberg false discovery rate method. For multiple logistic regression and the chi-squared test, a p-value < 0.05 was determined to be significant.

RESULTS

A total of 979 patients were included in this study, with an ASz frequency of 3.9 % (n = 38). For an overview of patient characteristics and the results of the univariate binary logistic regression analysis, (see Table 1). Among the evaluated independent variables, univariate binary logistic regression analysis revealed an increased risk of ASz in patients with a NIHSS score > 15 points at admission (47.4 vs. 33.7%, p = 0.09), 24 h after admission (47.8 vs. 23.5%, p = 0.025) and at discharge (33.3 vs. 9.5%, p = 0.021), which was also found for the numeric NIHSS score at admission, after 24 h and at discharge. Furthermore, patients with ASz were more likely than patients without ASz to have hypernatremia at admission (18.4 vs. 6.5%, p = 0.048) or pneumonia (47.4 vs. 29.4%, p = 0.07). A mRS score at discharge of 3-5 points was significantly more common in patients who suffered an ASz than in those who did not (87.0 vs. 49.3%, p = 0.017), which corresponds to greater disability in these patients after stroke.

Based on the univariate logistic regression, NIHSS score at admission (numeric), NIHSS after 24 h (numeric), hypernatremia at admission, and pneumonia were included in the final multiple logistic regression analysis. Because mRS at discharge and NIHSS score at discharge are typically ascertained beyond 7 days after stroke, they were not suitable for the prediction of ASz and therefore were not included. Following multiple logistic regression analysis, NIHSS score after 24 h was the strongest predictor for the occurrence of ASz (OR: 1.096, 95% CI: 1.036–1.159, p < 0.001), whereas NIHSS score at admission, pneumonia, and hypernatremia at admission did not reach the level of significance (Table 2 and Figure 1).

Seizures occurred at a median (minimum–maximum) of 2 (0–7) days after stroke onset. More than half (n = 22, 57.9 %) of the seizures occurred within the first 2 days, and over three-quarters (n = 29, 76.3%) of the seizures occurred within the first 3 days. For subgroup analysis of seizures, we divided them into two groups: seizure onset within the first 24 h after stroke (n = 11, 28.9%), and seizure onset later than 24 h after stroke (n = 27, 71.1%). We performed a multiple logistic regression analysis for each subgroup and included the following variables: NIHSS score at admission (numeric), NIHSS score after 24 h (numeric), hypernatremia at admission, and pneumonia. A high NIHSS score 24 h after admission was a risk factor only for the occurrence of seizures with onset later than 24 h after stroke (OR: 1.103, 95% CI: 1.035–1.174, p = 0.002). The other variables had no significant influence on stroke occurrence in the subgroup analysis (Table 3). Regarding seizure semiology, significantly more GTCSs (54.5 vs. 14.8%, p = 0.028) and more focal motor seizures (36.4 vs. 7.4%, p = 0.047) occurred in the subgroup of patients who had their seizure within the first 24 h after stroke. In contrast, there were significantly more seizures with impaired awareness in the subgroup of patients who suffered from ASz later than 24 h after stroke (77.8 vs. 9.1%, p = 0.003). For details, refer to Table 4.

DISCUSSION

The aim of this study was to investigate predictors of ASz in a well-defined study population of patients with LVO treated after the paradigm shift in stroke therapy to the widespread use and availability of mechanical thrombectomy (29). In our analysis, NIHSS score after 24 h was shown to be the strongest predictor for the occurrence of ASz in patients with ischemic stroke due to LVO. A higher NIHSS score correlates with a larger volume of damaged brain tissue and concomitant cortical involvement, which can explain the increased seizure risk (30). Our study showed a stronger predictive value of the NIHSS score after 24 h compared with the NIHSS score at admission. Furthermore, in the subgroup analysis, we demonstrated that a high NIHSS score was particularly associated with the occurrence of seizures later than 24 h after stroke.
| Predictor                              | Number of available data; % | Acute symptomatic seizure, n = 38 | No acute symptomatic seizure, n = 941 | Corrected p-value |
|----------------------------------------|-----------------------------|-----------------------------------|---------------------------------------|-------------------|
| Age                                    | Mean ± SD                   | 72.3 ± 11.6                       | 71.0 ± 14.0                           | 0.87              |
| Female gender                          | 979; 100%                   | 17; 44.7%                         | 453; 48.1%                            | 0.89              |
| NIHSS at admission ≤5°                 | 978; 99.9%                  | 4; 10.5%                          | 261; 27.8%                            | 0.18              |
| NIHSS at admission 6–15                | 978; 99.9%                  | 16; 42.1%                         | 362; 38.5%                            | 0.17              |
| NIHSS at admission > 15                | 978; 99.9%                  | 18; 47.4%                         | 317; 33.7%                            | 0.09              |
| NIHSS at discharge ≤5°                 | 607; 62.0%                  | 5; 27.8%                          | 396; 67.7%                            | 0.02              |
| NIHSS at discharge 6–15                | 6; 33.3%                    | 8; 34.8%                          | 219; 30.0%                            | 0.08              |
| NIHSS at discharge > 15                | 6; 33.3%                    | 11; 47.8%                         | 172; 23.5%                            | 0.025             |
| Vascular territory                     |                            |                                   |                                       |                   |
| Anterior circulation*                  | 979; 100%                   | 34; 89.5%                         | 776; 81.8%                            | 0.32              |
| Posterior circulation                  | 979; 100%                   | 3; 7.9%                           | 158; 16.8%                            | 0.17              |
| Both circulations                     | 979; 100%                   | 1; 2.6%                           | 13; 1.4%                              | 0.6               |
| Etiology                                |                            |                                   |                                       |                   |
| Unknown or ESUS*                       | 978; 99.9%                  | 12; 31.6%                         | 206; 21.9%                            | 0.91              |
| Atherothrombotic                       | 10; 26.3%                   | 3; 13.0%                          | 307; 50.7%                            | 0.017             |
| Cardioembolic                          | 1; 2.6%                     | 16; 42.1%                         | 367; 39.0%                            | 0.9               |
| Other                                   | 0; 0.0%                     | 0; 0.0%                           | 44; 4.7%                              | 1.0               |
| Acute stroke therapy                   |                            |                                   |                                       |                   |
| ST                                    | 979; 100%                   | 17; 44.7%                         | 413; 43.9%                            | 1.0               |
| MT                                    | 979; 100%                   | 19; 50.0%                         | 453; 48.1%                            | 0.93              |
| ST and MT                             | 979; 100%                   | 12; 31.6%                         | 252; 26.8%                            | 0.88              |
| MT with TICI ≥ 2b                      | 472; 100%                   | 17; 89.5%                         | 396; 85.2%                            | 0.85              |
| Preexisting therapies                  |                            |                                   |                                       |                   |
| Oral anticoagulant                     | 979; 100%                   | 5; 13.2%                          | 144; 15.3%                            | 0.88              |
| Antiplatelet                           | 979; 100%                   | 11; 28.9%                         | 302; 32.1%                            | 0.86              |
| Statin                                 | 979; 100%                   | 14; 36.8%                         | 250; 26.6%                            | 0.34              |
| Anti-seizure medication                | 979; 100%                   | 1; 2.6%                           | 61; 6.5%                              | 0.7               |
| Blood glucose level at admission       |                            |                                   |                                       |                   |
| <50 mg/dl                             | 954; 97.4%                  | 1; 2.6%                           | 2; 0.2%                               | 0.15              |
| ≥200 mg/dl                            | 966; 98.7%                  | 2; 5.3%                           | 80; 8.6%                              | 0.89              |
| Sodium level at admission              |                            |                                   |                                       |                   |
| ≤135 mmol/L                           | 763; 78%                    | 7; 18.4%                          | 60; 6.5%                              | 0.048             |
| Total cholesterol level > 200 mg/dl   |                            | 4; 18.2%                          | 152; 20.5%                            | 0.93              |
| Arterial hypertension                  | 979; 100%                   | 28; 73.7%                         | 686; 73.9%                            | 1.0               |
| Atrial fibrillation                    | 979; 100%                   | 16; 42.1%                         | 359; 38.2%                            | 0.85              |
| Chronic alcohol consumption            | 979; 100%                   | 2; 5.3%                           | 51; 5.4%                              | 1.0               |
| Neurodegenerative disease              | 979; 100%                   | 3; 7.9%                           | 53; 5.6%                              | 0.89              |
| Previous brain tumor                   | 979; 100%                   | 0; 0.0%                           | 7; 0.7%                               | 1.0               |
| Previous ischemic stroke              | 979; 100%                   | 11; 28.9%                         | 177; 18.8%                            | 0.29              |
| Hemorrhagic transformation             | 979; 100%                   | 2; 5.3%                           | 27; 2.0%                              | 0.75              |
| Pneumonia                              | 979; 100%                   | 18; 47.4%                         | 277; 29.4%                            | 0.07              |

*Indicates the reference category in regression analysis. P-values were corrected using the Benjamini–Hochberg false discovery rate method with a p-value < 0.1 considered statistically significant; significant values are marked bold. NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; ESUS, embolic stroke of undetermined source; ST, systemic thrombolysis; MT, mechanical thrombectomy; SD, standard deviation; Q1, first quartile; Q3, third quartile.
In contrast, no significant association was found between the NIHSS score and the occurrence of seizures within the first 24 h after stroke. In the literature, it was described that most seizures occurred within the first 24 h after stroke (31). This finding could not be reproduced in our study, but there were significant differences regarding seizure semiology. Significantly more focal motor seizures or GTCSs occurred within 24 h after stroke; beyond that period, seizures with reduced consciousness or NCSEs were more common. This observation could be explained by studies that did not include EEGs in their analysis, which may have led to an underestimation of the frequency of non-motor seizures or NCSEs and a predominance of motor seizures, which were more likely to occur in the first 24 h. However, besides differences in seizure semiology, ASz in our study showed a predominance within the first 48 h, which may be explained by different pathophysiological processes of ASz. Within the first hours, acute neuronal excitability due to ischemic disturbance of cellular integrity and pericellular milieu (i.e., electrolytes and neurotransmitters) may represent the prominent factor in seizure development, whereas subsequent tissue destruction and necrotic remodeling processes with surrounding inflammation could be responsible for the development of ASz beyond the first 24 h (32). This supports the hypothesis that in ASz occurring within 24 h after vascular occlusion, the extent of infarction is less important than the acute disturbances of cerebral integrity, for which a possible predisposition of the patient might be relevant. However, an increased risk in patients with a previous stroke, chronic alcohol consumption, previous brain tumor or a neurodegenerative disease was not observed. In this context, it would be of interest to investigate to what extent the risk of post-stroke epilepsy differs regarding the time of occurrence after stroke. Hemorrhagic transformation has been reported to be associated with an increased risk of ASz due to the deposition of blood degradation products such as hemosiderin, leading to local irritation of the brain (16). While hemorrhagic transformations have been consistently reported as an independent predictor of ASz (16, 33), this was not demonstrated in our study, although there was a tendency toward higher incidences of ASz in those patients. A possible reason for the missing of statistical significance might be the overall low incidence of hemorrhagic transformations in the included cohort in comparison to other trials (34).

It has been established that electrolyte imbalances are associated with ASz, with low sodium levels being particularly significant (35). Although hyponatremia seems to be more frequently associated with ASz, our study found an increased risk of ASz in patients with hypernatremia at admission (35). In particular, hypernatremia with a rapid onset, in contrast to chronic hypernatremia, is reported to show a significantly increased risk of ASz (35). Since hypernatremia was recorded

| Predictor                          | P-value | Exp(B) | 95% CI lower bound | 95% CI upper bound |
|------------------------------------|---------|--------|--------------------|--------------------|
| NIHSS after 24 h                   | <0.001  | 1.096  | 1.036              | 1.159              |
| NIHSS at admission                | 0.28    | 0.96   | 0.893              | 1.033              |
| Hypernatremia ≥ 145 mmol/L at admission | 0.69    | 1.360  | 0.301              | 6.154              |
| Pneumonia                          | 0.39    | 1.498  | 0.602              | 3.728              |

95% CI (95% confidence interval for Exp(B)). NIHSS, National Institutes of Health Stroke Scale. A p-value of < 0.05 was determined significant; significant values are marked in bold.
TABLE 3 | Multiple logistic regression analysis with subgroups of seizure patients.

| Predictor                          | Acute symptomatic seizure with stroke latency ≤ 24 h | Acute symptomatic seizure with stroke latency > 24 h |
|-----------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                   | P-value | Exp(B) | 95% CI lower bound | 95% CI upper bound | P-value | Exp(B) | 95% CI lower bound | 95% CI upper bound |
| NIHSS after 24 h                  | 0.224   | 1.066  | 0.962              | 1.182              | 0.002   | 1.103  | 1.035              | 1.174              |
| NIHSS at admission                | 0.571   | 1.040  | 0.909              | 1.189              | 0.150   | 0.940  | 0.866              | 1.022              |
| Hypernatremia ≥ 145 mmol/L at admission | 0.366   | 2.755  | 0.306              | 24.820             | 0.952   | 0.939  | 0.119              | 7.402              |
| Pneumonia                         | 0.309   | 0.319  | 0.035              | 2.884              | 0.157   | 2.101  | 0.752              | 5.870              |

95% CI [95% confidence interval for Exp(B)].

NIHSS, National Institutes of Health Stroke Scale. A p-value of < 0.05 was determined significant; significant values are marked in bold.

at admission, a further differentiation between acute or chronic hypernatremia was not possible. Besides initial electrolyte imbalances, critically ill patients on an intensive care unit or stroke unit bear an increased risk for the occurrence of subsequent hypernatremia (e.g., iatrogenic), which was not evaluated in our study (36). Furthermore, there was a trend toward an increased risk of seizures in patients with pneumonia in univariate regression analysis; however, this did not reach the significance level in multiple logistic regression analysis. This lack of effect might be attributed to the small sample size of those who suffered an ASz and the wide 95% confidence interval. In subgroup analysis, this tendency was particularly evident between pneumonia and the occurrence of seizures later than 24 h after stroke (OR: 2.101, 95% CI: 0.752–5.870, p = 0.157). Considering the predominance of ASz within the first 48 h and the increased risk of early pneumonia in patients with LVO due to general anesthesia during mechanical thrombectomy as well as stroke-related dysphagia, all pneumonias during hospital stay without formal classification into community- or hospital-acquired (>48 h after admission) were included (37). However, a more detailed analysis of the temporal association between the occurrence of pneumonia and ASz would be of interest and might be addressed in further studies. Acute non-neurological infections have been demonstrated as a predictive factor in other studies, but these studies usually did not include exclusively pneumonia (11, 13). Apart from concomitant fever, the epileptogenic effect of infections is attributed to the fact that the resulting inflammatory response, particularly by cytokines, lowers the seizure threshold and predisposes the brain to seizures (38).

Previous studies have shown associations with pre-existing diabetes mellitus and with the presence of hyperglycemia in experimental data (13, 39). In our study, hyperglycemia was not associated with an increased risk of ASz; however, hypoglycemia ≤ 50 mg/dl showed a trend toward more ASz. Since hypoglycemia ≤ 50 mg/dl was only observed in a very small number of patients (n = 3), this effect needs to be evaluated in future studies. As these factors are reversible causes, knowledge of their potential risk for ASz is important. Therefore, in patients with a recent stroke after LVO, regular monitoring of blood glucose and sodium levels should be performed with the aim of achieving normoglycemia and normonatremia. In addition, pneumonia prophylaxis should be practiced in addition to early treatment initiation after pneumonia has been diagnosed.

Regarding reperfusion therapies, in addition to the established systemic thrombolysis, mechanical thrombectomy has been widely available since 2015/2016 as a therapeutic option for emergency reopening of LVO (29, 40). Among the included patients, 50% with ASz and 48.1% without ASz received mechanical thrombectomy. Initial reports suggested that these methods may lead to an increased risk of ASz due to either neurotoxicity or reperfusion damage (41, 42). However, recent studies have not confirmed this and have instead supported the protective effect of reperfusion therapies in reducing the extent of infarction (21, 22). In concordance, this study, which examined only patients with ischemic stroke due to LVO, showed no association between treatment with systemic thrombolysis or mechanical thrombectomy and the occurrence of ASz. Previous studies described an increased risk of post-stroke epilepsy in severe strokes of the anterior circulation, which was attributed to a larger tissue damage (43). In our study, vascular territory (anterior or posterior circulation) was not found to be a predictive factor of ASz, although the overall smaller number of patients with posterior circulation infarcts should be noted. Further studies with a larger number of ASz and a volumetric evaluation of infarct size and location are required to determine their influence on the occurrence of ASz.

Despite a careful evaluation of all patients, this study had several limitations. Due to the limited number of ASz cases, the

TABLE 4 | Seizure semiology in patients with acute symptomatic seizures (ASz) in relation to time of stroke.

| Seizure semiology                  | Corrected | ASz with latency to stroke ≤ 24 h | ASz with latency to stroke > 24 h |
|------------------------------------|-----------|----------------------------------|----------------------------------|
|                                    | P-value   | (n = 11)                          | (n = 27)                          |
| Impaired awareness                 | 0.003     | n = 1 (9.1 %)                     | n = 21 (77.8 %)                   |
| (n = 22)                           |           |                                  |                                  |
| Focal motor seizure                | 0.047     | n = 4 (36.4 %)                    | n = 2 (7.4 %)                     |
| (n = 7)                            |           |                                  |                                  |
| GTCS                               | 0.028     | n = 6 (54.5 %)                    | n = 4 (14.8 %)                    |
| (n = 10)                           |           |                                  |                                  |

Impaired awareness includes non-convulsive status epilepticus (NCSE). P-values were corrected using the Benjamini–Hochberg false discovery rate method and p < 0.05 was considered statistically significant; significant values are marked in bold. GTCS, generalized tonic-clonic seizure.
possible influence of predictive factors might have been missed. This may explain why some previously described predictors did not reach statistical significance in our analysis. Nevertheless, while this study bears the risk of missing rare variables as predictors, the well-defined population of this single-center study allowed us to collect data on seizure semiology and time of seizure onset; this information was often lacking in larger study designs. The total number of ASz cases may still be underestimated without routine or continuous use of EEG, especially in intensive care units. Further studies with prospective designs to detect seizures by routine and continuous EEG in addition to systematic clinical examinations as well as studies with a larger sample size and long-term follow-up are necessary.

CONCLUSION

A high NIHSS score 24 hours after admission is one of the most important predictive factors for the occurrence of ASz in patients following ischemic stroke, especially for ASz occurring later than 24 h after stroke. Seizemiology of ASz differed significantly, with focal motor seizures or GTCSs occurring more frequently within the first 24 h after stroke, whereas seizures with impaired awareness or NCSE were more frequent beyond 24 h.

REFERENCES

1. Sander JW, Hart YM, Shorvon SD, Johnson AL. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general study. Lancet. (1990) 336:1267–71. doi: 10.1016/0140-6736(90)92560-P
2. Sung CY, Chu NS. Epileptic seizures in elderly people: aetiology and seizure type. Age Ageing. (1999) 19:25–30. doi: 10.1093/ageing/19.1.25
3. Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. (2020) 51:2418–27. doi: 10.1161/STROKEAHA.120.029606
4. Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. (2010) 51:671–5. doi: 10.1111/j.1528-1167.2009.02285.x
5. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, et al. Progressive derangement of perirrftact viable tissue in ischemic stroke. J Cereb Blood Flow Metab. (1992) 12:19-3-203. doi: 10.1038/jcbfm.1992.29
6. Luhmann HJ. Ischemia and lesion induced imbalances in cortical function. Prog Neurobiol. (1996) 48:131–66. doi: 10.1016/0079-6114(95)00042-9
7. Zoellner JP, Schmitt FC, Roseneow F, Kohlhase K, Seiler A, Strzelczyk A, et al. Seizures and epilepsy in patients with ischemic stroke. Neurol Res Pract. (2021) 1:63. doi: 10.1186/s42466-021-00161-w
8. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. Ilae official report: a practical clinical definition of epilepsy. Epilepsia. (2014) 55:475–82. doi: 10.1111/epi.12550
9. Wang JZ, Vyas MV, Sapounik G, Burneo JG. Incidence and management of seizures after ischemic stroke: systematic review and meta-analysis. Neurology. (2017) 89:1220–8. doi: 10.1212/WNL.0000000000004407
10. Leung T, Leung H, Soo YO, Mok VC, Wong KS. The prognosis of acute symptomatic seizures after ischemic stroke. J Neurol Neurosurg Psychiatry. (2017) 88:86–94. doi: 10.1136/jnnp-2015-311849
11. Zoellner JP, Kisselwitz B, Kaps M, Stein M, Konczalla J, Roth C, et al. National Institutes of Health Stroke Scale (NIHSS) on admission predicts acute symptomatic seizure risk in ischemic stroke: a population-based study involving 135,117 cases. Sci Rep. (2020) 10:3779. doi: 10.1038/s41598-020-60628-9

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following restrictions: Anonymised data will be made available after reasonable request due to german regulations on data protection.

ETHICS STATEMENT

This retrospective study was reviewed and approved by the Ethics Committee of the Medical Faculty of the Goethe University Frankfurt. Written informed consent for was not required for this study.

AUTHOR CONTRIBUTIONS

LT and KK conducted the study, collected the data, and wrote the original draft of the manuscript. LT, RG, and KK carried out the statistical analysis of the data. AS, WP, and KK were responsible for the methodological conceptualization of the study. AS was responsible for the supervision of the study. HS, FR, JS, and JZ contributed to the finalization of the manuscript and the formal analysis of the data. LT, AS, FR, WP, HS, RG, JS, JZ, and KK reviewed and revised the manuscript. All authors contributed to the manuscript and accepted the final version of the manuscript.

1. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. (2004) 35:1769–75. doi: 10.1161/01.STR.0000130989.17100.96
2. Krakow K, Sitzer M, Rosenow F, Steinmetz H, Foerch C. Predictors of acute poststroke seizures. Cerebrovasc Dis. (2010) 30:584–9. doi: 10.1159/000319777
3. Bladin CR, Alexandrov AV, Bellavance A, Bornstein N, Chambers R, Cote R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol. (2000) 57:1617–22. doi: 10.1001/archneur.57.11.1617
4. So EL, Annegers JE, Hauser WA, O’Brien PC, Wisnath JP. Population-based study of seizure disorders after cerebral infarction. Neurology. (1996) 46:350–5. doi: 10.1212/WNL.46.2.350
5. Beghi E, D’Alessandro R, Beretta S, Consoli D, Crespì V, Deloy L, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology. (2011) 77:1785–93. doi: 10.1212/WNL.0b013e3182364878
6. Zhang C, Wang X, Wang Y, Zhang JG, Hu W, Ge M, et al. Risk factors for post-stroke seizures: a systematic review and meta-analysis. Epilepsy Res. (2014) 108:1806–16. doi: 10.1016/j.eplepsres.2014.09.030
7. Strzelczyk A, Haag A, Raupach H, Herrendorf G, Hamer HM, Rosenow F. Prospective evaluation of a post-stroke epilepsy risk scale. J Neurol. (2010) 257:1322–6. doi: 10.1007/s00415-010-5520-9
8. Galovic M, Dohler N, Erdelyi-Canavese B, Felbeck A, Siebel P, Conrad J, et al. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the select score): a multivariable prediction model development and validation study. Lancet Neurol. (2018) 17:143–52. doi: 10.1016/S1474-4422(17)30404-0
9. Xu T, Wang Y, Yuan J, Chen Y, Luo H. Statin use and the risk of post-stroke seizures: a meta-analysis. Seizure. (2020) 83:63–9. doi: 10.1016/j.seizure.2020.10.004
10. Zoellner JP, Kisselwitz B, Mauroscat T, Roth C, Steinmetz H, Roseneow F, et al. Intravenous thrombolysis or mechanical thrombectomy do not increase risk of acute symptomatic seizures in patients with ischemic stroke. Sci Rep. (2020) 10:21083. doi: 10.1038/s41598-020-78012-y
11. Kohlhase K, Takko LM, Zoellner JP, Golbach R, Pfeilschifer W, Steinmetz H, et al. Mechanical thrombectomy does not increase the risk of acute symptomatic seizures in patients with an ischaemic stroke: a propensity score matching study. J Neurol. (2022). doi: 10.1007/s00415-022-10968-5
23. Zou S, Xiaomei W, Zhu B, Yu J, Yang B, Shi J. The pooled incidence of post-stroke seizure in 102,008 patients. Stroke Rehabil. (2015) 22:460–7. doi: 10.1179/107495715X.00000000062

24. Doria JW, Forcigs PB. Incidence, implications, and management of seizures following ischemic and hemorrhagic stroke. Curr Neurol Neurosci Rep. (2019) 19:37. doi: 10.1007/s11910-019-0957-4

25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening of reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X

26. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Toxsl. trial of org 10172 in acute stroke treatment. Stroke. (1993) 24:35–41. doi: 10.1161/01.STR.24.1.35

27. Fugate JE, Klunder AM, Kallmes DF. What is meant by “Tici”? AJNR Am J Neuroradiol. (2013) 34:1792–7. doi: 10.3174/ajnr.A3496

28. Fisher RS, Cross JH, D’Souza MA, Bohmann F, Lapa S, Misselwitz B, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. (2016) 387:1723–31. doi: 10.1016/S0140-6736(16)00163-X

29. Naylor J, Thevathasan A, Churilov L, Guo R, Xiong Y, Koome M, et al. Association between different acute stroke therapies and development of post-stroke seizures. BMC Neurol. (2018) 18:61. doi: 10.1186/s12883-018-1064-x

30. Tong DC, Yenari MA, Albers GW, O’Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (>6.5 hour) ischemic stroke. Neurology. (1998) 50:864–70. doi: 10.1221/wnl.50.4.864

31. Kim HJ, Park KD, Choi KG, Lee HW. Clinical predictors of seizure following the first post-stroke ischemic stroke. BMC Neurol. (2016) 16:212. doi: 10.1186/s12883-016-0729-6

32. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. (2009) 111:483–95. doi: 10.1016/j.clinneu.2009.04.001

33. Alemany M, Nunez A, Falip M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening of reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X

34. Galic MA, Riazi K, Pittman QJ. Cytokines and brain excitability. Front Neuroendocrinol. (2012) 33:116–25. doi: 10.1016/j.yfrne.2011.12.002

35. Uchino H, Smith ML, Bengzon J, Lundgren J, Siesjo BK. Characteristics of postischemic seizures in hyperglycemic rats. J Neurosci. (1996) 139:21–7. doi: 10.1016/0022-510X(96)0045-7

36. Goyal M, Menon BK, van Zwan WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. (2016) 387:1723–31. doi: 10.1016/S0140-6736(16)00163-X

37. Schaller-Paule MA, Christian F, Bohmann F, Lapa S, Misselwitz B, Kohlhase K, et al. Predicting poststroke pneumonia in patients with anterior large vessel occlusion: a prospective, population-based stroke registry analysis. Front Neurol. (2022) 13:824450. doi: 10.3389/fneur.2022.824450

Copyright © 2022 Tako, Strzelecky, Rosanow, Pfefschiller, Steinmetz, Gollbach, Schäfer, Zöllner and Kohlhase. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.